1. Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia

2. Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment
PED Pain Responders
Placebo
Milnacipran 100 mg/day
Milnacipran 200 mg/day
***
***
***
***
% of Patients
n=545 n= n=318
n=232 n= n=159
*** P≤0.001 vs placebo
PED= Patient Experience Diary

3. Proportion of Patients Achieving a PGIC Score of “Very Much Improved” or “Much Improved” at Week 12 of Stable Dose Treatment
PGIC Responders
Placebo
Milnacipran 100 mg/day
Milnacipran 200 mg/day
***
***
***
***
% of Patients
n=566 n= n=344
n=239 n= n=175
*** P<0.001 vs placebo
PGIC= Patient Global Impression of Change

4. 2-Measure Composite Responders
Percentage of 2-Measure Composite Responders at Week 12 of Stable Dose Treatment
2-Measure Composite Responders
Placebo
Milnacipran 100 mg/day
Milnacipran 200 mg/day
***
***
*** **
% of Patients
n=542 n= n=316
n=230 n= n=159
**P<0.01; *** P<0.001 vs placebo